News

Aptuit and Chiesi Farmaceutici are partnering in a search for idiopathic pulmonary fibrosis (IPF) treatments. Aptuit will be in charge of early-discovery efforts, which will include medicinal chemistry and pharmacology, drug metabolism and pharmacokinetics. Both companies will take part in the search for, and development of, compounds to treat IPF. “This…

Researchers found high levels of the anti-inflammatory protein CC16 in the blood of idiopathic pulmonary fibrosis (IPF) patients, suggesting it plays a role in the disease. The research showed 50 percent higher levels of the protein in IPF patients than in non-IPF patients with other conditions, and three times the level…

A number of important discoveries, therapeutic developments, and events related to pulmonary fibrosis (PF) were reported daily by Pulmonary Fibrosis News throughout 2016. Now that the year is over, it is time to briefly review the articles that appealed most to our readers. Here are the 10 most-read articles of 2016,…

So what is grief? Isn’t it just lots of crying? That is such a normal question. Grief is the process of letting go of someone or something that was deeply important to you. Grief is very different for each person, and comes in waves…

A single microRNA was found to play a key role in lung fibrosis by regulating several signaling pathways involved in the release of pro-fibrotic signals. The study, “miR-323a-3p regulates lung fibrosis by targeting multiple profibrotic pathways,” was published in the journal JCI Insight. MicroRNAs are small…

The Viscira production company has won an international award for a 3D animated video about idiopathic pulmonary fibrosis (IPF) that it did in collaboration with Roche. The Academy of Interactive and Visual Arts gave its Silver Davey Award to Viscira for the best video in its category. The Davey…